Gilead’s Viread likely to be included in health insurance

Published: 2012-07-10 06:58:00

Updated: 2012-07-10 06:58:00

The Health Insurance Review and Assessment Service (HIRA) said on Jun 28 that it would not list the U.S. drugmaker Gilead Sciences’ Viread (tenofovir) into the positive list unless Yuhan Corp., local exclusive distributor, accepts its insurance price that is lower than that of Bristol Myers Squib...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK